{"id":"NCT04788511","sponsor":"Novo Nordisk A/S","briefTitle":"Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity","officialTitle":"Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-16","primaryCompletion":"2023-04-18","completion":"2023-04-18","firstPosted":"2021-03-09","resultsPosted":"2024-06-11","lastUpdate":"2025-02-26"},"enrollment":529,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"Semaglutide","otherNames":[]},{"type":"DRUG","name":"Placebo (semaglutide)","otherNames":[]}],"arms":[{"label":"Semaglutide","type":"EXPERIMENTAL"},{"label":"Placebo (semaglutide)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking \"dummy\" medicine.\n\nParticipants will either get semaglutide or \"dummy\" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm.\n\nDuring the study participants will have talks with the study staff about healthy lifestyle choices including healthy food and physical activity.\n\nThe study will last for approximately 59 weeks. Participants will have 11 clinic visits and 1 phone call with the study doctor. Women: Women cannot take part if they are pregnant, breast-feeding or plan to become pregnant during the study period.","primaryOutcome":{"measure":"Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)","timeFrame":"From baseline (week 0) to end of treatment (week 52)","effectByArm":[{"arm":"Semaglutide 2.4 mg","deltaMin":16.8,"sd":17.9},{"arm":"Placebo","deltaMin":10.3,"sd":17.3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":93,"countries":["United States","Argentina","Australia","Canada","Czechia","Denmark","Germany","Hungary","Israel","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["37635157","37622681","39222642","38739118","38599221","37993201","37952180"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":263},"commonTop":["COVID-19","Nausea","Diarrhoea","Constipation","Vomiting"]}}